

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/38, 31/405, 31/445, C07D 209/90, 471/02, 495/16, 513/16	A1	(11) International Publication Number: WO 98/18464 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/19183 (22) International Filing Date: 23 October 1997 (23.10.97) (30) Priority Data: ① 60/029,849 ✓ 30 October 1996 (30.10.96) ✓ US ✓ (71) Applicant (for all designated States except US): ① ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). ✓ (72) Inventors; and (75) Inventors/Applicants (for US only): ① BACH, Nicholas, J. [US/US]; 7215 South Meridian Street, Indianapolis, IN 46217. (US) ② DILLARD, Robert, D. [US/US]; 7243 West 92nd Street, Zionsville, IN 46077. (US) ③ DRAHEIM, Susan, E. [US/US]; 6125 Burlington Avenue, Indianapolis, IN 46220. (US) ④ MORIN, John, M., Jr. [US/US]; 9 Roselawn Avenue, Brownsburg, IN 46112 (US). ✓ (74) Agents: PALMBERG, Arleen et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> IPD. 1 appl. 4 Invs. IPC: A61K 31/38, 31/405, 31/445, 31/44 C07D 209/90 471/02 495/16 513/16	
(54) Title: SUBSTITUTED TRICYCLICS ✓		
(57) Abstract A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA ₂ mediated release of fatty acids for treatment of conditions such as septic shock.		I PER 12/5/98.